Pentavalent antimonial

(Redirected from Pentavalent antimonials)

Pentavalent antimonials (also abbreviated pentavalent Sb or SbV) are a group of compounds used for the treatment of leishmaniasis. They are also called pentavalent antimony compounds.

Types

edit

The first pentavalent antimonial, urea stibamine, was synthesised by the Indian scientist Upendranath Brahmachari in 1922. Though it caused a dramatic decline in deaths due to leishmaniasis, it fell out of favour in the 1950s due to higher toxicity compared to sodium stibogluconate.[citation needed]

The compounds currently available for clinical use are:

The pentavalent antimonials can only be given by injection: there are no oral preparations available.[citation needed]

Alternatives

edit

In many countries, widespread resistance to antimony has meant that liposomal amphotericin or miltefosine are now used in preference.[2]

Side effects

edit

Cardiotoxicity, reversible kidney failure, pancreatitis, anemia, leukopenia, rash, headache, abdominal pain, nausea, vomiting, arthralgia, myalgia, thrombocytopenia, and transaminase elevation.[citation needed]

References

edit
  1. ^ Lima EB, Porto C, Motta JCO, Sampaio RNR.Treatment of American cutaneous leishmaniasis. An Bras Dermatol. 2007;82(2):111-24.
  2. ^ Olliaro P, Guerin P, Gerstl S (2005). "Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004". Lancet Infect Dis. 5 (12): 763–774. doi:10.1016/S1473-3099(05)70296-6. hdl:10144/66036. PMID 16310148.